Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics, Inc. reported insider-related open-market sales of its common stock by Atlas Venture funds associated with director Bruce Booth. On June 22, 2026, entities reported aggregate sales of 31,798 shares at weighted average prices around $103–$104 per share under a pre-established Rule 10b5-1 trading plan.
The shares are held directly by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest. After these transactions, related entities reported holdings of 613,762 and 3,472,340 Kymera shares, indicating they continue to hold substantial positions.
Kymera Therapeutics director‑associated entities reported sizeable June stock sales alongside an option exercise. Across June 17–22, entities linked to Bruce Booth sold a net 478,198 shares of Kymera common stock in open‑market transactions at prices generally around the low‑ to low‑$100 range.
Most shares are held directly by Atlas Venture Fund X and Atlas Venture Opportunity Fund I; Booth is a member of their general partners and disclaims Section 16 beneficial ownership beyond any pecuniary interest. On June 17, he exercised stock options for 11,741 shares at $20.00 per share and sold all those shares at a weighted‑average price of $89.98, leaving no direct common‑stock holdings but 28,127 fully vested options outstanding that expire on August 19, 2030. Several sales were executed under Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options for 2,500 shares of common stock at $21.05 per share and on the same day sold 2,500 shares in an open-market transaction at $99.00 per share. Following these transactions, he directly holds 50,195.438 shares of common stock. The trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.
KYMR reported officer/affiliate sales disclosed on Form 144. The excerpt lists multiple sales by Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P. and Bruce Booth between 04/14/2026 and 06/18/2026, showing individual transactions with share counts and cash amounts.
The filings identify the security as Common Stock and note prior private placement issuance on 03/11/2020. The excerpt provides per-transaction share counts (for example, 100,928 shares on 06/18/2026) and corresponding cash amounts, but does not state aggregate proceeds to the issuer.
KYMR filed Form 144 reporting the resale of 243,976 shares of Common Stock. The notice lists multiple sales by Atlas Venture funds and affiliated individuals on 04/15/2026, 04/22/2026, 06/17/2026, and 06/18/2026, with per‑trade share counts and cash proceeds shown.
The entries identify the sales as resale transactions tied to a prior Private Placement (03/11/2020) and show cash proceeds for each trade; the filings are routine resale notices under Section 144.
KYMR notice reports a proposed transaction and recent affiliate sales. The filing lists an exercise of stock options resulting in 2,500 shares to be sold on 06/22/2026 for cash. It also discloses prior 10b5-1 sales by Noah Goodman on 04/09/2026 (5,764 shares, $500,582.20), 04/09/2026 (2,500 shares, $222,500.00), 04/10/2026 (2,000 shares, $174,700.00), and 04/14/2026 (1,347 shares, $121,230.00).
KYMR affiliates reported proposed sales of Common Stock on Form 144. The notice lists multiple dispositions by Atlas Venture entities and by Bruce Booth on 04/15/2026, 04/22/2026, and 06/18/2026
Examples include Atlas Venture Fund X, L.P. proposing a sale of 92,169 shares on 06/18/2026 for $8,330,667.41, and Bruce Booth reporting 11,741 shares on 06/18/2026 for $1,056,443.24. The transactions are reported as resale of previously acquired common stock from a private placement.
KYMR affiliate sales reported under Rule 144. The excerpt lists multiple sales of Common Stock by affiliated holders and individuals, including transactions on 04/15/2026, 04/22/2026, and 06/18/2026. Reported sellers include Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P., and Bruce Booth. Sales are shown with share counts and gross proceeds per line.
KYMR reported proposed dispositions of Common Stock under Form 144 by certain holders, listing specific sale dates and share counts. The filing lists multiple reported sales in April 2026, including 2,750 shares on 04/15/2026 and 5,900 shares on 04/22/2026 by identified holders. The transactions are presented as reported sale notices for shares originally issued in a Private Placement dated 03/11/2020.
KYMR filed notices of proposed sales of Common Stock by affiliated holders, listing multiple transactions dated 04/14/2026 through 04/22/2026. The filing shows individual sales by insiders/holders including Bruce Booth and Atlas Venture Fund X, L.P., with examples of specific share amounts and dollar amounts.
Examples include Bruce Booth selling 4,159 shares on 04/14/2026 for $374,199.56 and Atlas Venture Fund X, L.P. selling 2,750 shares on 04/15/2026 for $247,765.57. The notice lists multiple small secondary sales by founders and venture funds across April 2026.